VESICARE LS
PeakNDAORALSUSPENSIONPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VESICARE LS is an oral suspension formulation of solifenacin succinate, an antimuscarinic agent approved in 2020 for overactive bladder (OAB) symptoms. The drug works by blocking muscarinic receptors to reduce urinary urgency, frequency, and incontinence. The liquid formulation enables flexible dosing and may improve adherence in patients with swallowing difficulties.
$0.032BPart D
Peak4.8 years to LOEAt peak lifecycle maturity with modest Part D penetration; brand team likely optimizing market share against established competitors rather than driving growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on VESICARE LS at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.